8 October 2024 UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101.
Cratering shares in Cambridge, Massachusetts-based inflammatory disease company Third Harmonic Bio reflect a loss in confidence after a Phase I failure. 16 December 2022
Big pharma pairing AstraZeneca and Merck & Co announced a rare setback with their blockbuster PARP inhibitor Lynparza (olaparib) in prostate cancer on Thursday. 16 December 2022
Japan-based Sosei Group’s shares rose 8.4% to 2,222 yen today, as it announced it is collaborating with US pharma major Eli Lilly to discover, develop and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR) targets linked with diabetes and metabolic diseases. 16 December 2022
Announcing further plans to accelerate and broaden the clinical development of its cancer immunotherapy pipeline in the Asia-Pacific region, Germany’s BioNTech said that the first regional clinical trial sites for the company’s mRNA-based cancer immunotherapies are planned to be activated in Taiwan to initially evaluate BioNTech’s cancer product candidate BNT113 against head and neck cancer. 16 December 2022
Positive results from the Phase III GLOW trial could pave the way for a new kind of cancer treatment, an antibody targeting the Claudin-18.2 protein. 16 December 2022
Of the 20 drugs currently being developed for primary progressive multiple sclerosis (PPMS), three are now in Phase III development, offering hope to the patients, who have very few treatment options in comparison to patients affected by relapsing remitting multiple sclerosis (RRMS). 16 December 2022
The Association of the British Pharmaceutical Industry (ABPI) has warned UK lawmakers that an existing pricing agreement is unsustainable, and that the cost of agreed rebates are too high. 15 December 2022
Privately held US clinical-stage biotech Cybrexa Therapeutics today announced the appointment of Michael Needle as chief medical officer. 15 December 2022
The European Commission has granted marketing authorization for Livmarli (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) aged two months and older. 15 December 2022
Pennsylvania, USA-based CNS specialist Vallon Pharmaceuticals’ stock price soared an initial 230% to $0.85, after the company unveiled plans to merge its operations with privately-held biotech GRI Bio in an all-stock transaction. 15 December 2022
Adding to a string of approved indications for the interleukin (IL) and IL-4 blocking antibody, the European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Union to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. 15 December 2022
A Danish company developing a vaccine against group B streptococcus (GBS) - an infection often known as Strep B - has 72 million ($77 million) euros more to spend. 15 December 2022
A novel targeted protein degradation (TPD) candidate from Kymera Therapeutics is to be advanced by its research and development partner, Sanofi. 15 December 2022
US eyecare pharma company Harrow Health’s shares jumped 15% to $12.77 after it announced a binding agreement for the acquisition of the exclusive US commercial rights to five Food and Drug Administration (FDA) approved ophthalmic products from Swiss pharma giant Novartis 15 December 2022
Prices for a wide range of drugs in the Russian pharmaceutical retail sector are steadily growing due to a significant reduction of their supplies and disappearance from retail shelves. 15 December 2022
The Russian government together with some leading domestic financial corporations will provide support to domestic producers of active pharmaceutical ingredients (APIs) that will primarily be in the form of provision of preferential loans and other benefits for them, reports The Pharma Letter’s local correspondent. 15 December 2022
As the year draws to a close, this article presents some of the wins of the orphan drug community in terms of US FDA approvals, while highlighting challenges faced by the sector and looking ahead to the expectations of the next year. 15 December 2022
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
Sage Therapeutics’ share price fell 11% to $6 in pre-market activity on Tuesday, after it announced disappointing top-line results from LIGHTWAVE. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
The UK has launched a new Regulatory Innovation Office (RIO), with the goal of accelerating new technologies, particularly in sectors like biotech and healthcare, by reducing regulatory barriers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Some two-and-a-half years after buying the Novo Holdings portfolio company ReViral and its respiratory syncytial virus (RSV) candidate sisunatovir in a deal worth up to $525 million, US pharma giant Pfizer may have signalled an early end to the pricey project. 9 October 2024
US pharma major Bristol Myers Squibb’s recent approval from the US Food and Drug Administration (FDA) for Cobenfy (xanomeline and trospium chloride) for the treatment of adults with schizophrenia is a win for the company. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.